We advised GH Research on the IPO and Nasdaq Listing

Davis Polk advised GH Research PLC on its SEC-registered initial public offering of 11,499,999 ordinary shares for total gross proceeds of approximately $184 million. GH Research is listed on the Nasdaq Global Market under the ticker symbol “GHRS.”

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research’s initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression (TRD).

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Heita Miki, Jonathan I. Stempel and Christian Knoble. Partner David R. Bauer and associate Yana Kipnis provided intellectual property advice. Partner Adam Kaminsky and associate Charlotte R. Fabiani provided executive compensation advice. Members of the Davis Polk team are based in the New York and Washington DC offices.